

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Morris 1



Section 1. Identifying Inform	ation			
Given Name (First Name) Andrea	2. Surname (Last Nar Morris	me)	3. Date 04-May-202	20
4. Are you the corresponding author?	☐ Yes ✓ No	Correspond Bartolome	ng Author's Name R. Celli	
5. Manuscript Title Pharmacotherapy and Lung Function D	ecline in Patients wit	h Chronic Obstru	tive Pulmonary Disease: A	Systematic Review
6. Manuscript Identifying Number (if you kn	ow it)			
Section 2. The Work Under Co	onsideration for P	ublication		
Did you or your institution at any time recei any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of intereing If yes, please fill out the appropriate info Excess rows can be removed by pressing	but not limited to grands: est? Yes ormation below. If yo	nts, data monitoring	board, study design, manusci	ript preparation,
Name of Institution/Company	Grant? Personal Fees?	Non-Financial Support?	Other? Comments	
SSK			I am an employee of GSK stocks/shares	f GSK and hold
SSK			This study was fund NCT01313676 (GSK 113782): Study to U Mortality and Morb (SUMMIT).	study number Inderstand
Section 2				
Section 3. Relevant financial	activities outside	the submitted	vork.	
Place a check in the appropriate boxes in				egardless of amount
of compensation) with entities as descri clicking the "Add +" box. You should rep				•

Morris 2



Name of Entity	Grant?	Personal Fees	Non-Financial Support?	Other?	Comments		
GSK				✓	I am an employee of GSK and hold GSK stocks/shares		
Section 4. Intellectual Propert	y Pate	ents & Cop	pyrights				
Do you have any patents, whether plann	ed, pend	ing or issue	ed, broadly releva	nt to the	work? Yes No		
Section 5. Relationships not c	overed	above					
Are there other relationships or activities potentially influencing, what you wrote i				influence	d, or that give the appearance of		
Yes, the following relationships/cond							
No other relationships/conditions/circumstances that present a potential conflict of interest							
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.							
Section 6. Disclosure Stateme	nt						
Based on the above disclosures, this form below.		omatically	generate a disclo	sure state	ment, which will appear in the box		
AM s an employee of and owns shares in	i GSK.						

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Morris 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent



Section 1.	Identifying Inform	nation				
1. Given Name (Fir Bartolome	st Name)	2. Surname (Last N Celli	lame)		3. Date 06-May-2020	
4. Are you the corr	responding author?	√ Yes No)			
5. Manuscript Title Pharmacotherap		ecline in Patients v	vith Chronic Obstru	ıctive Pulm	onary Disease: A Systematic Rev	iew
6. Manuscript Ider	ntifying Number (if you kn	now it)				
Section 2.	The Work Under Co	onsideration for	Publication			
any aspect of the si statistical analysis,	ubmitted work (including	but not limited to g			nt, commercial, private foundation, e dy design, manuscript preparation,	tc.) for
If yes, please fill o		ormation below. If y		n one entity	press the "ADD" button to add	a row.
Name of Institut	ion/Company	Grant? Person	al Non-Financial Support?	Other?	Comments	
Glaxo Smith Kline			V		tatistical analysis and editorial upport	
Section 3.	Relevant financial	activities outsid	e the submitted	work.		
of compensation clicking the "Add Are there any rele) with entities as descri	ibed in the instruct port relationships t est?	ions. Use one line f	or each ent	al relationships (regardless of am ity; add as many lines as you nee 36 months prior to publication	ed by
Name of Entity		Grant? Person		Other?	Comments	
Astra Zeneca		✓		√ R	Research site	
GlaxoSmithKline					Consulting and scientific comittee	
Boehringer Ingelheim	ı				Consulting	



Name of Entity	Grant?	Personal Fees	Non-Financial Support?	Other?	Comments	
Sanofi-Aventis		✓			Consulting	
Menarini		\checkmark			Consulting	
Chiesi		✓			Consulting	
Pulmonx		✓			Consulting	
Section 4. Intellectual Propert	ty Pate	ents & Cop	pyrights			
Do you have any patents, whether plann Section 5. Relationships not of	ed, pend	ing or issue		nt to the	work? Yes 🗸 No	
Are there other relationships or activities potentially influencing, what you wrote a yes, the following relationships/conditions/circle. At the time of manuscript acceptance, journals may ask authors to the conditions of the c	s that reac in the sub ditions/cir rcumstand ournals wi	ders could pomitted work cumstance ces that pre	rk? es are present (expessent a potential of ers to confirm and	olain belc conflict o	ow): f interest sary, update their disclosure statem	nents.
Based on the above disclosures, this form below. Dr. Celli reports personal fees and other Boehringer Ingelheim, personal fees from outside the submitted work; .	n will auto	ra Zeneca, p	oersonal fees fron	n GlaxoSı	mithKline, personal fees from	



Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Hartley 1



Section 1. Identifying Inform			
Identifying Inform	ation		
Given Name (First Name) Benjamin F.	2. Surname (Last Name) Hartley		3. Date 04-May-2020
4. Are you the corresponding author?	Yes ✓ No	Corresponding Authors Bartolome R. Celli	or's Name
5. Manuscript Title Pharmacotherapy and Lung Function De	ecline in Patients with Cl	nronic Obstructive Pul	monary Disease: A Systematic Review
6. Manuscript Identifying Number (if you kno	ow it)		
Section 2. The Work Under Co	nsideration for Publ	ication	
Did you or your institution at any time receivany aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of interesting the state of the	but not limited to grants, d		
If yes, please fill out the appropriate info Excess rows can be removed by pressing	rmation below. If you ha	ve more than one ent	ity press the "ADD" button to add a row.
Name of Institution/Company	Grant	on-Financial Other?	Comments
/eramed Ltd			Employed by Veramed Ltd who are contracted to work for GSK
Section 3. Relevant financial a	activities outside the	submitted work.	
Place a check in the appropriate boxes ir of compensation) with entities as described clicking the "Add +" box. You should rep	oed in the instructions. U	Ise one line for each e	ntity; add as many lines as you need by
Are there any relevant conflicts of interest	st? ✓ Yes No		
If yes, please fill out the appropriate info	rmation below.		
Name of Entity	Grant	on-Financial Other?	Comments
GlaxoSmithKline			Formerly employed by GSK and hold shares in the company

Hartley 2



Section 4.	Late Heat and December 10 Commission
	Intellectual Property Patents & Copyrights
Do you have any	patents, whether planned, pending or issued, broadly relevant to the work? Yes V
Section 5.	Relationships not covered above
	relationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?
Yes, the follo	wing relationships/conditions/circumstances are present (explain below):
✓ No other rela	ationships/conditions/circumstances that present a potential conflict of interest
	anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. Irnals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the abo	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box
Mr. Hartley repo	orts other from Veramed Ltd, other from GlaxoSmithKline, during the conduct of the study; .

Evaluation and Feedback

 $Please\ visit\ \underline{http://www.icmje.org/cgi-bin/feedback}\ to\ provide\ feedback\ on\ your\ experience\ with\ completing\ this\ form.$

Hartley 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Crim 1



Section 1. Identifying Inform					
Identifying Inform	nation				
Given Name (First Name) Courtney	2. Surname (Last Name Crim	e)	3. Date 04-May-2020		
4. Are you the corresponding author?	Yes ✓ No	✓ No Corresponding Author's Name Bartolome R. Celli			
5. Manuscript Title Pharmacotherapy and Lung Function D	Decline in Patients with	Chronic Obstructi	ve Pulmonary Disease: A Systematic Review		
6. Manuscript Identifying Number (if you kr	now it)				
Section 2. The Work Under Co	onsideration for Pu	blication			
any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of interest.	g but not limited to grant est? Yes Normation below. If you	s, data monitoring bo	vernment, commercial, private foundation, etc.) fo pard, study design, manuscript preparation, ne entity press the "ADD" button to add a row		
Name of Institution/Company		Non-Financial O	ther? Comments		
SK			I am an employee of GSK and hold GSK stocks/shares		
SK			This study was funded by GSK, NCT01313676 (GSK study number 113782): Study to Understand Mortality and Morbidity In COPD Trial (SUMMIT).		
Section 3. Relevant financial	activities outside tl	he submitted wo	ork.		
Place a check in the appropriate boxes of compensation) with entities as descr clicking the "Add +" box. You should re	in the table to indicate ibed in the instructions port relationships that	whether you have s. Use one line for e were present dur i	financial relationships (regardless of amount each entity; add as many lines as you need by ng the 36 months prior to publication.		
Are there any relevant conflicts of intered If yes, please fill out the appropriate info		IU			

Crim 2



Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments		
GSK				✓	I am an employee of GSK and hold GSK stocks/shares		
Section 4. Intellectual Property							
Intellectual Propert	y Patei	nts & Co _l	pyrights				
Do you have any patents, whether plann	ed, pendir	ng or issue	ed, broadly releva	nt to the	work? Yes No		
Section 5. Relationships not c	overed a	bove					
Are there other relationships or activities potentially influencing, what you wrote i				nfluence	d, or that give the appearance of		
Yes, the following relationships/cond	litions/circ	umstance	es are present (exp	olain belo	w):		
✓ No other relationships/conditions/cir	No other relationships/conditions/circumstances that present a potential conflict of interest						
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.							
Section 6. Disclosure Stateme	nt						
Based on the above disclosures, this form below.	n will auto	matically (generate a disclos	sure state	ment, which will appear in the box		
CC is an employee of and owns shares in	n GSK.						

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Crim 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Quasny 1



Section 1. Identifying Information	
1. Given Name (First Name) 2. Surname (Last Name) 3. Date Holly Quasny 04-May-2020	
4. Are you the corresponding author?	
5. Manuscript Title Pharmacotherapy and Lung Function Decline in Patients with Chronic Obstructive Pulmonary Disease: A Systematic Review	
6. Manuscript Identifying Number (if you know it)	
Section 2. The Work Under Consideration for Publication	
Did you or your institution at any time receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)? Are there any relevant conflicts of interest? Yes No	r
Section 3. Relevant financial activities outside the submitted work.	
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were present during the 36 months prior to publication . Are there any relevant conflicts of interest? Yes No	
Section 4. Intellectual Property Patents & Copyrights	
Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes No	
Are there any relevant conflicts of interest? Yes No	

Quasny 2



Section 5.	
	Relationships not covered above
	elationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?
Yes, the follow	wing relationships/conditions/circumstances are present (explain below):
No other rela	tionships/conditions/circumstances that present a potential conflict of interest
	anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. rnals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the abo	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Quasny 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Anderson 1



Section 1.	Identifying Inform	nation					
1. Given Name (Fi	rst Name)	2. Surname (Last Name) Anderson	3. Date 04-May-2019				
4. Are you the cor	responding author?	Yes ✓ No	Corresponding Author's Name Bartolome R. Celli				
5. Manuscript Title Pharmacotherapy and Lung Function Decline in Patients with Chronic Obstructive Pulmonary Disease: A Systematic Review							
6. Manuscript Ider	ntifying Number (if you kr	now it)					
Section 2.	The Work Under Co	onsideration for Public	cation				
any aspect of the s statistical analysis,	ubmitted work (including	g but not limited to grants, da	a third party (government, commercial, private foundation, etc.) for ta monitoring board, study design, manuscript preparation,				
Section 3.							
Section 5.	Relevant financial	activities outside the s	ubmitted work.				
of compensation) with entities as descri	ibed in the instructions. Us	ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by re present during the 36 months prior to publication.				
Are there any rel	evant conflicts of intere	est?					
	I						
Section 4.	Intellectual Proper	rty Patents & Copyric	phts				
Do you have any	patents, whether plan	ned, pending or issued, br	oadly relevant to the work? Yes V No				

Anderson 2



Section 5. Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
✓ Yes, the following relationships/conditions/circumstances are present (explain below):
No other relationships/conditions/circumstances that present a potential conflict of interest
JA is an employee of and owns shares in GSK.
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
JA is an employee of and owns shares in GSK

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Anderson 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Vestbo 1



Section 1.							
Identifying Inform	nation						
1. Given Name (First Name) Jørgen	2. Surname (Last Name) Vestbo		3. Date 04-May-2020				
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding Author's Name Bartolome R. Celli					
5. Manuscript Title Pharmacotherapy and Lung Function [n Decline in Patients with Chronic Obstructive Pulmonary Disease: A Systematic Review						
6. Manuscript Identifying Number (if you k	now it)						
Section 2. The Work Under C	onsideration for Publi	cation					
any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of inter	g but not limited to grants, d	ata monitoring board, st	ent, commercial, private foundation, etc.) fo udy design, manuscript preparation, ity press the "ADD" button to add a row				
Excess rows can be removed by pressing							
Name of Institution/Company	Grant	n-Financial Other?	Comments				
ilaxoSmithKline			I was partly reimbursed for my work as Chair of the SUMMIT Steering Committee				
Section 3. Relevant financial	activities outside the	submitted work.					
Place a check in the appropriate boxes of compensation) with entities as descr clicking the "Add +" box. You should re	ibed in the instructions. U	se one line for each er	ntity; add as many lines as you need by				
Are there any relevant conflicts of inter	est? Yes No						
If yes, please fill out the appropriate inf	ormation below.						
Name of Entity	Grant	n-Financial Support?	Comments				
GlaxoSmithKline			Consultancy for COPD Phase 2 and 3 program and payment for lectures including service in speaker bureau				

Vestbo 2



Name of Entity	Grant?	Personal Fees	Non-Financial Support?	Other?	Comments		
Chiesi Pharmaceuticals		✓			Consultancy for COPD Phase 2 and 3 program and payment for lectures including service in speaker bureau		
Boehringer-Ingelheim		✓			Consultancy for COPD Phase 2 and 3 program and payment for lectures including service in speaker bureau		
Novartis		✓			Consultancy for COPD Phase 2 and 3 program and payment for lectures including service in speaker bureau		
AstraZeneca		✓			Consultancy for COPD Phase 2 and 3 program and payment for lectures including service in speaker bureau		
Section 4. Intellectual Property Patents & Copyrights Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes V No							
Section 5. Relationships not c	overed	above					
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?							
Yes, the following relationships/conditions/circumstances are present (explain below):							
No other relationships/conditions/cir	cumstan	ces that pre	esent a potential o	conflict o	finterest		
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements							

Vestbo 3

On occasion, journals may ask authors to disclose further information about reported relationships.

Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Vestbo reports personal fees from GlaxoSmithKline, during the conduct of the study; personal fees from GlaxoSmithKline, personal fees from Chiesi Pharmaceuticals, personal fees from Boehringer-Ingelheim, personal fees from Novartis, personal fees from AstraZeneca, outside the submitted work;

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Vestbo 4



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Yates 1



Section 1. Identifying	g Information							
1. Given Name (First Name) Julie	2. Surname (Last Name) Yates	3. Date 04-May-2020						
4. Are you the corresponding aut	hor? Yes 🗸 No	Corresponding Author's Name Bartolome R. Celli						
5. Manuscript Title Pharmacotherapy and Lung Function Decline in Patients with Chronic Obstructive Pulmonary Disease: A Systematic Review								
6. Manuscript Identifying Numbe	er (if you know it)							
Section 2. The Work	Jnder Consideration for Public	ation						
Did you or your institution at any time receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)? Are there any relevant conflicts of interest? Yes Ves								
Section 3. Relevant fi	nancial activities outside the s	ubmitted work.						
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were present during the 36 months prior to publication . Are there any relevant conflicts of interest? Yes Vo								
Section 4. Intellectua	l Property Patents & Copyrig	ıhts						
Do you have any patents, whe	ther planned, pending or issued, bro	oadly relevant to the work? Yes V No						

Yates 2



Section 5. Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
✓ Yes, the following relationships/conditions/circumstances are present (explain below):
No other relationships/conditions/circumstances that present a potential conflict of interest
JCY is an employee of and owns shares in GSK.
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
JCY is an employee of and owns shares in GSK.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Yates 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent



Section 1.	Identifying Inform	nation								
1. Given Name (Fi Fernando	rst Name)	2. Surname Martinez	2. Surname (Last Name) Martinez 3. Date 04-May-2020							
4. Are you the cor	responding author?	Yes	√ No	-	Corresponding Author's Name Bartolome R. Celli					
5. Manuscript Title Pharmacotherapy and Lung Function Decline in Patients with Chronic Obstructive Pulmonary Disease: A Systematic Review										
6. Manuscript Ide	ntifying Number (if you k	now it)								
Section 2.	The Work Under C	onsideratio	n for Pu	ıblication						
	submitted work (includin					ent, commercial, private foundation, etc.) for udy design, manuscript preparation,				
•	evant conflicts of inter	est? 🗸 Yes	5 N	lo						
	out the appropriate inf be removed by pressir			have more than	one enti	ty press the "ADD" button to add a row.				
Name of Institut	, ·	Grant? Po		Non-Financial Support?	Other?	Comments				
GSK				✓		Supports the parent study				
Section 3.	Relevant financial	activities o	utside tl	he submitted	work.					
of compensation	n) with entities as desci	ribed in the in	struction	s. Use one line fo	or each er	cial relationships (regardless of amount ntity; add as many lines as you need by a 36 months prior to publication .				
	evant conflicts of inter			lo						
If yes, please fill o	out the appropriate inf	ormation belo	ow.							
Name of Entity		Grant	ersonal Fees	Non-Financial Support?	Other?	Comments				
AtraZeneca			✓	✓	✓	COPD Ad Boards, Steering Committee (honoraria, travel support)				
Afferent/Merck					√	IPF Steering Committee (publication)				



Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments
Boheringer Ingelheim		√	✓	√	COPD Advisory Board (honorarium travel) support; ILD DSMB, IPF Steering Committee, Study presentations (honoraria, travel support, publication)
Bristol Myers Squibb				\checkmark	teleconference without compensation
Chiesi				\checkmark	COPD Ad Board (travel support)
Canadian Respiratory Society		✓	✓		COPD CME presentation (honorarium, travel support)
CME Outfitters		✓	✓		COPD CME presentation (honorarium, travel support)
CSL Behring		✓	✓		IPF Ad Board (honorarium, travel support)
Dartmouth University		✓			IPF CME presentation (honorarium)
France Foundation		✓			IPF CME presentation
Gala		✓			COPD Ad Board
Genentech		✓	✓		Asthma DSMB, IPF Ad Board (honorarium and travel support)
GlaxoSmithKline	✓	✓	✓	√	COPD Ad Boards, Steering Committee, DSMB (honoraria and travel support)
Inova Fairfax		✓	✓		COPD CME presentation (honorarium and travel support)
MDMagazine		✓	✓		COPD CME (honorarium and travel support)
NYP Methodist Hospital Brooklyn		✓	✓		COPD CME presentation (honorarium and travel support); IPF CME presentation (honorarium and travel support)
Miller Communications		✓	✓		COPD and IPF CME presentations (honoraria and travel support)
National Association for Continuing Education		✓	✓		COPD and IPF CME presentations (honoraria and travel support)
Nitto				✓	Steering Committee without compensation
Novartis		✓	\checkmark		COPD CME presentation (honoraria and travel support)
New York University		✓			ILD CME presentation (honorarium)
Patara/Respivant		✓	✓		IPF Steering Committee (honorarium and travel support)



Pearl	\checkmark			COPD Ad Board (honorarium)
Peer View	✓	\checkmark		COPD and IPF CME presentations (honoraria and travel support)
Physicians Education Resource	\checkmark			COPD CME (honoraria)
ProMedior	\checkmark			IPF Steering Committee
Rare Diseases Healthcare Communications	✓	✓		IPF CME presentation (honorarium and travel support)
Rockpointe Communications	\checkmark			COPD CME presentation (honorarium)
Sanofi/Regeneron	✓	✓		COPD Ad Board (honorarium and travel support)
Biogen			✓	DSMB and Steering Committee without compensation
unovion	\checkmark	✓		COPD Ad Board (honorarium and travel support)
eva	✓	\checkmark		COPD Ad Board (honorarium and travel support)
twoXR			✓	teleconference without compensation
University of Birmingham Alabama	\checkmark			IPF CME presentation (jonorarium and travel support)
JpToDate	✓			COPD and ILD CME enduring materia (honoraria)
/eracyte		✓		IPF Steering Committee
/indico	\checkmark			IPF CME presentation (honorarium)
VebMD/MedScape	✓	\checkmark		COPD CME presentations (honoraria and travel support)
Zambon		\checkmark	✓	IPF Ad Board (travel support) and NIF study in kind supprot
ProTerrix Bio		\checkmark		COPD consultation and NIH study in kind support



Cartinu 5	
Section 5.	Relationships not covered above
	elationships or activities that readers could perceive to have influenced, or that give the appearance of ncing, what you wrote in the submitted work?
	wing relationships/conditions/circumstances are present (explain below): tionships/conditions/circumstances that present a potential conflict of interest
	anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements rnals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Martinez reports grants from AstraZeneca, during the conduct of the study; personal fees, non-financial support and other from AtraZeneca, other from Afferent/Merck, personal fees, non-financial support and other from Boheringer Ingelheim, from Bristol Myers Squibb, other from Chiesi, personal fees and non-financial support from Canadian Respiratory Society, personal fees and non-financial support from CME Outfitters, personal fees and non-financial support from CSL Behring, personal fees from Dartmouth University, personal fees from France Foundation, personal fees from Gala, personal fees and non-financial support from Genentech, grants, personal fees, non-financial support and other from GlaxoSmithKline, personal fees and non-financial support from Inova Fairfax, personal fees and non-financial support from MDMagazine, personal fees and non-financial support from NYP Methodist Hospital Brooklyn, personal fees and nonfinancial support from Miller Communications, personal fees and non-financial support from National Association for Continuing Education, from Nitto, personal fees and non-financial support from Novartis, personal fees from New York University, personal fees and non-financial support from Patara/Respivant, personal fees from Pearl, personal fees and nonfinancial support from Peer View, personal fees from Physicians Education Resource, from ProMedior, personal fees and non-financial support from Rare Diseases Healthcare Communications, personal fees from Rockpointe Communications, personal fees and non-financial support from Sanofi/Regeneron, from Biogen, personal fees and non-financial support from Sunovion, personal fees and non-financial support from Teva, from twoXR, personal fees from University of Birmingham Alabama, personal fees from UpToDate, non-financial support from Veracyte, personal fees from Vinidco, personal fees and non-financial support from WebMD/MedScape, non-financial support and other from Zambon, nonfinancial support from ProTerrix Bio, outside the submitted work; .

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent



Section 1. Identifying Inforn	nation							
Given Name (First Name) Nicholas	2. Surname (Last Na Cowans	2. Surname (Last Name) Cowans 3. Date 04-May-2020						
4. Are you the corresponding author?	Yes Vo	•	Corresponding Author's Name Bartolome R. Celli					
5. Manuscript Title Pharmacotherapy and Lung Function Decline in Patients with Chronic Obstructive Pulmonary Disease: A Systematic Review								
6. Manuscript Identifying Number (if you k	now it)							
Section 2. The Work Under C	onsideration for F	Publication						
Did you or your institution at any time receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)? Are there any relevant conflicts of interest? Ves No If yes, please fill out the appropriate information below. If you have more than one entity press the "ADD" button to add a row. Excess rows can be removed by pressing the "X" button.								
Name of Institution/Company	Grant? Personal	Non-Financial Support?	Other? Cor	nments				
ilaxoSmithKline Plc.				tudy was funded by SmithKline Plc.				
eramed Ltd.			✓ Contrunder	n employee of Veramed Ltd, a fact Research Organization rtaking contracted statistical ses of studies funded by SmithKline Plc.				
					'			
Section 3. Relevant financial	activities outside	the submitted v	vork.					
Place a check in the appropriate boxes of compensation) with entities as descr clicking the "Add +" box. You should re	ibed in the instructio	ons. Use one line fo	r each entity; a	add as many lines as you need	d by			
Are there any relevant conflicts of inter		No						
If yes, please fill out the appropriate information below.								



Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments		
Veramed Ltd.				√	I am an employee of Veramed Ltd, a Contract Research Organization undertaking contracted statistical analyses of respiratory studies funded by GlaxoSmithKline Plc.		
Section 4. Intellectual Propert	y Pate	ents & Cop	pyrights				
Do you have any patents, whether plann	ed, pend	ing or issue	ed, broadly releva	nt to the	work? Yes 🗸 No		
Section 5. Relationships not c	overed	above					
Are there other relationships or activities potentially influencing, what you wrote i				nfluence	d, or that give the appearance of		
Yes, the following relationships/cond	litions/cir	cumstance	es are present (exc	olain belo	w):		
No other relationships/conditions/cir			•				
At the time of manuscript acceptance, jo On occasion, journals may ask authors to					· ·		
Section 6. Disclosure Stateme	nt						
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.							
NJC is employed by Veramed Ltd, a Confunded by GSK.	tract Rese	earch Organ	nisation undertak	ing contr	acted statistical analyses of studies		



Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent



Section 1. Identifying Information	ation								
1. Given Name (First Name) Peter	2. Surname (Last Name) Calverley								
4. Are you the corresponding author?	Yes ✓ No	No Corresponding Author's Name Bartolome R. Celli							
5. Manuscript Title Pharmacotherapy and Lung Function Decline in Patients with Chronic Obstructive Pulmonary Disease: A Systematic Review									
6. Manuscript Identifying Number (if you kno	ow it)								
		_							
Section 2. The Work Under Co	onsideration for Publi	cation							
Did you or your institution at any time received any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of interest fyes, please fill out the appropriate inform Excess rows can be removed by pressing	but not limited to grants, dansest? Yes No	ata monitoring board, st	udy design, manuscript preparation,						
Name of Institution/Company	Grant? Personal No	n-Financial Other?	Comments						
GSK	✓ □		I was a member of the SUMMIT Science Committee supported by GSK.						
Section 3. Relevant financial activities outside the submitted work.									
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were present during the 36 months prior to publication . Are there any relevant conflicts of interest? Yes No If yes, please fill out the appropriate information below.									
Nov. Charles	Personal No	n-Financial							
Name of Entity	Grant	Other Other	Comments						
GSK	✓		Paid for the conduct of the SUMMIT study and speaking						



Name of Entity	Grant?	Personal		Other?	Comments		
Boehringer Ingelheim		Fees •	Support!		Advised on development of new trials and spoken for BI at sponsored meetings		
Novartis		✓			For chairing a DSMB.		
Recipharm		✓	✓		For advising on develpment of erdosteine and speaking at related meetings		
Zambon		✓			Speaker at ERS symposium		
Phillips Respironics		✓			Advice on ventilator development and speaking at related meetings		
Section 4. Intellectual Propert	y Pate	ents & Cop	pyrights				
Do you have any patents, whether plann	ed, pendi	ing or issue	ed, broadly releva	nt to the	work? ☐ Yes ✓ No		
Section 5. Relationships not c	overed :	above					
Are there other relationships or activities potentially influencing, what you wrote i				nfluence	d, or that give the appearance of		
Yes, the following relationships/cond	itions/cir	cumstance	es are present (exp	olain belo	w):		
No other relationships/conditions/cir	cumstan	ces that pre	esent a potential (conflict o	finterest		
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.							
Section 6. Disclosure Statement							
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.							
PMAC has advised Boehringer Ingelheim, GSK, Recipharm and Phillips Respironics on the design and conduct of clinical trials and has spoken at meetings sponsored by these companies and by Zambon. He chairs a data safety monitoring board for Novartis. He has no stock holdings in any pharmaceutical company or connection with the tobacco industry.							



Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.